Does CANAKINUMAB Cause Pulmonary embolism? 344 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 344 reports of Pulmonary embolism have been filed in association with CANAKINUMAB (Ilaris). This represents 3.3% of all adverse event reports for CANAKINUMAB.
344
Reports of Pulmonary embolism with CANAKINUMAB
3.3%
of all CANAKINUMAB reports
91
Deaths
278
Hospitalizations
How Dangerous Is Pulmonary embolism From CANAKINUMAB?
Of the 344 reports, 91 (26.5%) resulted in death, 278 (80.8%) required hospitalization, and 311 (90.4%) were considered life-threatening.
Is Pulmonary embolism Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 344 reports have been filed with the FAERS database.
What Other Side Effects Does CANAKINUMAB Cause?
Pyrexia (1,327)
Inappropriate schedule of drug administration (1,238)
Drug ineffective (1,078)
Inappropriate schedule of product administration (944)
Pain (858)
Condition aggravated (771)
Malaise (684)
Off label use (557)
Arthralgia (555)
Rash (505)
What Other Drugs Cause Pulmonary embolism?
RIVAROXABAN (3,282)
LENALIDOMIDE (2,976)
APIXABAN (2,714)
ETHINYL ESTRADIOL\ETONOGESTREL (2,370)
TESTOSTERONE (2,043)
RITUXIMAB (1,764)
ADALIMUMAB (1,663)
PREDNISONE (1,586)
METHOTREXATE (1,508)
DEXAMETHASONE (1,336)
Which CANAKINUMAB Alternatives Have Lower Pulmonary embolism Risk?
CANAKINUMAB vs CANDESARTAN
CANAKINUMAB vs CANDESARTAN CILEXETIL
CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE
CANAKINUMAB vs CANGRELOR
CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN